Gov’t Prioritizes Safety, Precision, Speed in Producing COVID-19 Vaccine
Date 24 Juli 2020
In a bid to provide protection to the people, the Government is working to produce COVID-19 vaccine that prioritizes safety, precision, and speed.
“We have several cooperation to produce vaccine, including the collaboration between state-owned pharmaceutical company Bio Farma and Chinese company Sinovac which is going through a phase-three clinical trial process. Hopefully the vaccine can be completed within a specific period of time and will be mass produced later,” Spokesperson of the COVID-19 National Working Committee Wiku Adisasmito said at the Presidential Office, Jakarta, Friday (24/7).
Nevertheless, he asserted that besides that cooperation, the Government also started an initiative to materialize vaccine self-sufficiency.
“We surely want the vaccine to be produced by Indonesian companies. So far, state-owned company Bio Farma, and pharmaceutical company PT. Kalbe have declared their intentions, and more alternatives and potentials in Indonesia will open soon,” Wiku said.
The Spokesperson went on to say that a team of experts in the field of vaccines and drugs is formed to ensure that the vaccine sample is suitable and appropriate to give protection to the Indonesian people.
“I need to emphasize that in the vaccine development, the Government of Indonesia is prioritizing three important aspects, namely safety, precision, and speed,” he said adding that safety means the vaccine can protect all Indonesians without side effects and precision means it must help develop immunity against COVID-19 strain in Indonesia.
Meanwhile, speed means that the vaccine must immediately protect the people. Therefore, tests including clinical trials must be conducted in fast and proper manner.
“In speed aspect, the vaccine production must be made correctly and in sufficient quantity to cover all Indonesian people who need protection,” he concluded. (MAY/EN)
Translated by : Rany Anjany
Reviewed by: Yuyu Mulyani